Preoperative planning PSMA-PET in Melanoma Surgery (PPPIMS)

Royal Marsden NHS Foundation Trust0 个研究点目标入组 16 人开始时间: 2024年9月26日最近更新: 2024年9月30日

适应症

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方: Royal Marsden NHS Foundation Trust
入组人数: 16
主要终点: 1. Proportion of successes for detecting metastatic disease by PSMA PET-CT, measured at a single timepoint before surgery

暂无简介。

•Males =18 years of age
•Biopsy-proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site

•Patients unable to give voluntary written informed consent to participate in this study
•Patients not willing to complete all the study assessments
•Patients who are females
•Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists
•Patients who have or have previously been diagnosed with prostate cancer
•Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
•Patients not fluent in English

1. Proportion of successes for detecting metastatic disease by PSMA PET-CT, measured at a single timepoint before surgery

1. Proportion of successes for detecting metastatic disease by both PSMA PET-CT and FDG PET-CT, measured at a single timepoint before surgery2. The Standardised Uptake Value (SUV) by both FDG PET-CT and PSMA PET-CT, measured at a single timepoint before surgery

发起方